Healing Reimagined
Immunicom’s Immunopheresis™ is designed to empower
patients to best live their lives while receiving revolutionary
cancer treatment.This unique immunotherapy is intended
to meaningfully improve patients’ quality of life and
avoid typical side-effects.
LATEST MILESTONE
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
A transformative immunotherapy
Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis™ technology platform.
The breakthrough Immunopheresis approach uses a therapeutic device that works outside of the body and is designed to treat cancer, inflammatory, renal, and autoimmune diseases by removing barriers from the blood that block the immune system from doing its job.
Our Recognition
Designed to treat
multiple diseases
multiple diseases
Worldwide clinical trials are underway at leading hospitals to evaluate Immunopheresis in several cancer types, both as a singular therapy and in combination with other treatments.
Latest News
April 30, 2021
Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference
April 21, 2021
Immunicom Recognized as One of the Best Places to Work in the U.S.
March 26, 2021
Oncology Investors to Hear “Cancer Device Company of the Year” Immunicom Present at MedInvest Conference
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
Our Mission
To improve the quality of life for patients
in a meaningful way and expedite their
path to a healthy future.
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team